Alexion Pharmaceuticals Inc. wowed investors on its earnings yet again, with second-quarter revenues that soundly beat expectations and prompted the Cheshire, Conn.-based firm to raise for the second time its 2011 sales guidance for paroxysmal nocturnal hemoglobinuria (PNH) drug Soliris (eculizumab). Read More
Casting biopharma as a villain in the ongoing saga of federal deficits and increased health care costs, a Senate committee is looking for ways to strengthen the Centers for Medicare & Medicaid Services' (CMS) role in containing prescription drug prices Read More
As a way of getting clinical trials "under way and successfully concluded," BioSante Pharmaceuticals Inc., of Lincolnshire, Ill., has licensed its melanoma vaccine to the John P. Hussman Foundation for $100,000 up front, with up to $39 million in milestones. Read More
When formed in 2010, the founders of TWi Biotechnology Inc. always had in mind a two-pronged strategy: going after generic markets to get relatively quick returns while investing in longer-term innovative drug development programs. Read More
Sangamo BioSciences Inc., of Richmond, Calif., reported preclinical data showing the use of zinc finger nucleases in the production of genetically modified pigs. Data, published in the Proceedings of the National Academy of Sciences, described a method for generating animals in which a chosen gene is knocked out from the genome. Read More
Celsion Corp., of Columbia, Md., raised $18.4 million, $13 million of which came from a registered direct offering to institutional investors and $5.4 million of which came from a private placement with other investors. Read More
Inotek Pharmaceuticals Corp., of Lexington, Mass., completed the first two of three stages of a multiple-dose Phase IIb trial of its eye drop candidate, INO-8875, in patients with glaucoma or ocular hypertension. Based on the achievement of the milestone, Inotek's investors have committed the final tranche of their previous $20 million funding round and have committed an additional $3.7 million to expand the final portion of the ongoing clinical trial by increasing the number of subjects and the duration of treatment in the final phase. Read More
